Sangamo Therapeutics Stock Analysis

Sangamo Stock Analysis Notes

About 39.0% of the company shares are owned by institutional investors. The company recorded a loss per share of 1.24. Sangamo Therapeutics had not issued any dividends in recent years. Sangamo Therapeutics, Inc., a clinical-stage biotechnology company, focuses on translating science into genomic medicines that transform patients lives using platform technologies in gene therapy, cell therapy, genome editing, and genome regulation. Sangamo Therapeutics, Inc. was incorporated in 1995 and is headquartered in Brisbane, California. Sangamo Therapeutics is traded on NASDAQ Exchange in the United States. To find out more about Sangamo Therapeutics contact ChB MB at 510 970 6000 or learn more at https://www.sangamo.com.

Sangamo Therapeutics Investment Alerts

Sangamo Therapeutics Upcoming and Recent Events

Sangamo Largest EPS Surprises

View All Earnings Estimates

Sangamo Therapeutics Environmental, Social, and Governance (ESG) Scores

Sangamo Stock Institutional Investors

Note, although Sangamo Therapeutics' institutional investors appear to be way more sophisticated than retail investors, it remains unclear if professional active investment managers can reliably enhance risk-adjusted returns by an amount that exceeds fees and expenses.

Sangamo Market Capitalization

The company currently falls under 'Small-Cap' category with a current market capitalization of 563.24 M.

Sangamo Profitablity

Management Efficiency

Sangamo Therapeutics has return on total asset (ROA) of (0.5829) % which means that it has lost $0.5829 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (1.9405) %, meaning that it created substantial loss on money invested by shareholders. Sangamo Therapeutics' management efficiency ratios could be used to measure how well Sangamo Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. As of the 28th of November 2024, Return On Tangible Assets is likely to grow to -1.48. In addition to that, Return On Capital Employed is likely to grow to -2.21. At this time, Sangamo Therapeutics' Total Assets are very stable compared to the past year. As of the 28th of November 2024, Non Currrent Assets Other is likely to grow to about 19 M, while Other Assets are likely to drop 0.95.

Technical Drivers

As of the 28th of November, Sangamo Therapeutics has the Semi Deviation of 4.53, risk adjusted performance of 0.1605, and Coefficient Of Variation of 505.29. In relation to fundamental indicators, the technical analysis model makes it possible for you to check existing technical drivers of Sangamo Therapeutics, as well as the relationship between them.

Sangamo Therapeutics Price Movement Analysis

Sangamo Therapeutics Insider Trading Activities

Sangamo Therapeutics Outstanding Bonds

Sangamo Therapeutics Predictive Daily Indicators

Sangamo Therapeutics Corporate Filings

Sangamo Therapeutics Forecast Models

Sangamo Therapeutics' time-series forecasting models are one of many Sangamo Therapeutics' stock analysis techniques aimed at predicting future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Sangamo Therapeutics' historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.

Stock analysis is the technique used by a trader or investor to examine and evaluate how Sangamo Therapeutics prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Sangamo shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas. a specific sector, or an individual Stock such as Sangamo Therapeutics. By using and applying Sangamo Stock analysis, traders can create a robust methodology for identifying Sangamo entry and exit points for their positions.

We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. Sangamo analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. Sangamo analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.

Sangamo Therapeutics stock analysis indicators help investors evaluate how Sangamo Therapeutics stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing and determine when trading Sangamo Therapeutics shares will generate the highest return on investment. By understating and applying Sangamo Therapeutics stock analysis, traders can identify Sangamo Therapeutics position entry and exit signals to maximize returns.

Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Sangamo Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in population. To learn how to invest in Sangamo Stock, please use our How to Invest in Sangamo Therapeutics guide.You can also try the Portfolio Rebalancing module to analyze risk-adjusted returns against different time horizons to find asset-allocation targets.

Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Sangamo Therapeutics. If investors know Sangamo will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Sangamo Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

The market value of Sangamo Therapeutics is measured differently than its book value, which is the value of Sangamo that is recorded on the company's balance sheet. Investors also form their own opinion of Sangamo Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Sangamo Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Sangamo Therapeutics' market value can be influenced by many factors that don't directly affect Sangamo Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Sangamo Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Sangamo Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Sangamo Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.